| Cardiac implications for the use of β2-adrenoceptor agonists for the management of muscle wasting | |||||||||||
Abstract | |||||||||||
| There are proposals for the implementation of β2-adrenoceptor agonists for the management of muscle wasting diseases. The idea has been initiated by studies in animal models which show that β2-adrenoceptor agonists cause hypertrophy of skeletal muscle. Their use in clinical practice will also need an understanding of possible effects of activation of human heart β2-adrenoceptors. Consequences could include an increased probability of arrhythmias in susceptible patients. | |||||||||||
Publication details | |||||||||||
| |||||||||||